Vaishali Pharma Ltd. (IN:VAISHALI)
:VAISHALI
Want to see IN:VAISHALI full AI Analyst Report?
VAISHALI Stock Chart & Stats
₹8.04
-₹0.33(-1.95%)
At close: 4:00 PM EST
₹8.04
-₹0.33(-1.95%)
Day’s Range― - ―
52-Week Range₹4.75 - ₹13.59
Previous CloseN/A
Volume565.66K
Average Volume (3M)399.32K
Market Cap
₹742.84M
Enterprise Value₹888.39M
Total Cash (Recent Filing)₹10.46M
Total Debt (Recent Filing)₹156.01M
Price to Earnings (P/E)21.3
Beta1.23
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding107,192,130
10 Day Avg. Volume443,817
30 Day Avg. Volume399,324
Financial Highlights & Ratios
PEG Ratio-11.89
Price to Book (P/B)0.26
Price to Sales (P/S)0.17
P/FCF Ratio-0.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained ~15% year-over-year revenue growth provides a durable top-line foundation, signaling expanding customer demand or market share. Over months, healthy revenue expansion supports reinvestment in products, absorbs SG&A, and underpins a path back to operating profitability if cost trends stabilize.
Stable Balance Sheet And Equity BaseA healthy equity base with moderate leverage gives the company financial flexibility to fund working capital, absorb shocks, and pursue selective investments. This stability reduces refinancing risk and supports longer-term strategic initiatives without immediate pressure to cut operating programs.
Positive Net Profit Margin MaintainedDespite operating headwinds, a positive net profit margin indicates the company retains some bottom-line profitability from current operations or non-operating items. This provides a buffer while management addresses operational inefficiencies, aiding cash generation prospects if margins improve.
Bears Say
Negative Operating And Free Cash FlowMaterial negative operating and free cash flow in 2025 is a durable constraint on the company's ability to self-fund working capital, capex, or growth. Over several months this necessitates external financing or asset sales, increasing cost of capital and reducing strategic flexibility.
Negative EBIT And Declining Gross MarginsA negative EBIT combined with falling gross margins signals structural cost pressures or weaker pricing power. Unless addressed, these trends erode operating leverage and make sustained profitability unlikely, forcing either margin restoration or transformational business changes.
Earnings Deterioration (negative EPS Growth)Negative EPS growth of roughly -12% indicates declining reported earnings, which can reduce retained capital and investor confidence. Over a multi-month horizon this constrains reinvestment capacity, weakens credit metrics, and may necessitate cost cutting or external funding to sustain operations.
Vaishali Pharma Ltd. News
VAISHALI FAQ
What was Vaishali Pharma Ltd.’s price range in the past 12 months?
Vaishali Pharma Ltd. lowest stock price was ₹4.75 and its highest was ₹13.59 in the past 12 months.
What is Vaishali Pharma Ltd.’s market cap?
Vaishali Pharma Ltd.’s market cap is ₹742.84M.
When is Vaishali Pharma Ltd.’s upcoming earnings report date?
Vaishali Pharma Ltd.’s upcoming earnings report date is Jun 03, 2026 which is in 13 days.
How were Vaishali Pharma Ltd.’s earnings last quarter?
Vaishali Pharma Ltd. released its earnings results on Feb 13, 2026. The company reported ₹0.101 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.101.
Is Vaishali Pharma Ltd. overvalued?
According to Wall Street analysts Vaishali Pharma Ltd.’s price is currently Overvalued.
Does Vaishali Pharma Ltd. pay dividends?
Vaishali Pharma Ltd. does not currently pay dividends.
What is Vaishali Pharma Ltd.’s EPS estimate?
Vaishali Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaishali Pharma Ltd. have?
Vaishali Pharma Ltd. has 107,192,130 shares outstanding.
What happened to Vaishali Pharma Ltd.’s price movement after its last earnings report?
Vaishali Pharma Ltd. reported an EPS of ₹0.101 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.126%.
Which hedge fund is a major shareholder of Vaishali Pharma Ltd.?
Currently, no hedge funds are holding shares in IN:VAISHALI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaishali Pharma Ltd.
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers active pharmaceutical ingredients (APIs), including antibiotics, anti-ulcer, anti-inflammatory/analgesic/anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, anti-diarrheal/anti-protozoal/anti-parasitic, anti-viral, anti-epileptic, anti-asthmatic, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helmintic drugs, as well as excipients, topical steroids, corticosteroids, and enzymes. The company also provides formulation products, such as antibiotics/antibacterial, anti-platelet, laxative, anti-ulcer/enzyme, anti-asthmatic, anti-malarial, anti-cold/anti-allergic/anti-viral, anti-psychotic, anti-fungal, anti-inflammatory/analgesic/anti-pyretic, anti-diabetic, cardiac, vitamins, topical steroids/corticosteroids, and other formulations. In addition, it offers veterinary pharmaceutical, nutraceutical, oncology, herbal, and surgical products. The company was founded in 1989 and is headquartered in Mumbai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Krebs Biochemicals & Industries Ltd.
―